Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin for LUTS in Female MS Patients
NCT07614321Phase 4Recruiting
- Sponsor
- Atlantic Health System
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in lower urinary tract symptoms (LUTS) comparing Silodosin with Placebo (2 arms). Primary endpoint: American Urological Association Symptom Score at 8 weeks. Started Apr 2026; status: recruiting.
02
Drugs
silodosin
03
Conditions
lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT07614321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614321.